DrugRisk Update: Swiss Insurer Joins Yaz Lawsuit Over Blood Clots

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
yaz lawsuit
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

New York, NY (PRWEB) January 10, 2013

The prescription drug resource center DrugRisk.com is alerting patients who have taken the birth control drugs Yaz or Yasmin of the adition of new information to the site showing Switzerland’s largest health insurer has joined in a lawsuit over allegations that Yasmin caused blood clots and pulmonary embolism.

“The mission of DrugRisk is to improve patient safety through education, including the latest medication warnings, recalls, studies and litigation news. Many visitors don’t yet know the extent of health warnings and litigation surrounding the birth control drugs Yaz and Yasmin,” explains DrugRisk representative Ryan Mayer.

DrugRisk previously advised that thousands of Yaz lawsuits over blood clots filed in the U.S. have been consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

The resource center reported on Bayer’s most recent financial statements, which show the company has spent nearly $750 million so far to settle approximately 3,500 of these claims, at an average of or around $214,000 per case.* Bayer confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

Now, new information added to the site shows Switzerland’s largest health insurer, CSS, has joined in a case filed by a young women who suffered weeks of hospitalization for pulmonary embolism after taking Yasmin, for treatment costing almost $650,000.**

DrugRisk has also added a warning from France’s Health Ministry that they will stop reimbursements for oral contraceptives like Yaz and Yasmin in March over concerns that the drugs increase risks of blood clots.***

Last fall, The American College of Obstetricians and Gynecologists also warned that birth control pills containing drospirenone, such as Yaz and Yasmin, may have a higher risk of causing blood clots.****

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

The Drug Risk Resource Center cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012
**Reuters: “Swiss health insurer makes claim against Bayer over Yasmin pill,” January 9, 2013
*** reuters.com/article/2013/01/03/france-contraception-idUSL5E9C31XG20130103
****Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”


Contact